tirzepatide

semaglutide

retatrutide

HOT SELL

ATX-304 is an investigational oral drug designed to restore metabolic activity by activating AMPK, a central regulator of cellular energy that declines with age.

As the first AMPK Network Activator to enter clinical development, it aims to mimic the metabolic benefits of exercise at the cellular level. Its mechanism targets two complementary cellular processes simultaneously: it increases both cellular glucose uptake and mitochondrial respiration, resulting in a balanced increase of energy supply and demand that drives up whole-body metabolic rate.

Unlike prior AMPK-targeting approaches that risked impairing cellular energy balance, ATX-304 activates AMPK without decreasing cellular ATP levels, a differentiation confirmed in mechanistic studies.

Orforglipron raws

Orforglipron is a once-daily oral, non-peptide small-molecule GLP-1 receptor agonist approved for chronic weight management and type 2 diabetes. It can be taken at any time of day without food or water restrictions .

Selling Points: Its non-peptide structure enables unrestricted oral dosing at any time without fasting or water timing requirements—a key differentiator from oral peptide GLP-1s .

As a Gs-biased agonist with minimal β-arrestin recruitment, it may sustain receptor activation with less desensitization .

Small-molecule manufacturing is also less complex and costly than peptide synthesis, potentially improving global access .

SANA is a first-in-class investigational oral small molecule that targets energy expenditure rather than appetite suppression for obesity and metabolic disease .

Mechanism & Efficacy: SANA is a nitroalkene derivative of salicylate that activates creatine-dependent thermogenesis in adipose tissue, increasing mitochondrial respiration and energy burning independently of UCP1 and AMPK pathways .

Preclinical data also showed preservation of lean muscle mass alongside significant fat loss and reduced liver steatosis .

Selling Points: Its complementary mechanism offers an alternative for patients who cannot tolerate GLP-1 therapies, targeting energy expenditure instead of appetite .

Preclinical evidence suggests muscle-sparing weight loss, a key differentiator from GLP-1 agonists associated with lean mass loss . Flexible oral or subcutaneous dosing may support adherence

GHK-CU Raws

GHK-Cu (copper tripeptide-1) is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine, with levels declining significantly with age . It was first isolated by Loren Pickart in 1973 and is widely studied for tissue regeneration and anti-aging applications .

Key Functions and Efficacy: GHK-Cu stimulates collagen and glycosaminoglycan synthesis in fibroblasts, supporting skin firmness, elasticity, and wound repair .
It also possesses antioxidant and anti-inflammatory properties, reducing oxidative damage and modulating inflammatory cytokines .
In skincare, human studies (typically 8–12 weeks) report improvements in skin laxity, firmness, fine lines, and pigmentation . It also supports hair follicle health and may increase hair growth and follicle size .

Selling Points: Its dual action on collagen synthesis and copper delivery distinguishes it from standard peptides, as copper is essential for enzymatic activity in skin repair . The compound has decades of cosmetic safety data and is generally well-tolerated topically.

SNAP-8 (Acetyl Octapeptide-3) is a synthetic peptide specifically designed for topical use in anti-aging skincare. It is a longer, more stable, and reportedly more effective version of the well-known peptide Argireline (Acetyl Hexapeptide-8).

Its name is an acronym for "Synaptic Neurotransmission Blocking Peptide", which describes its primary mechanism of action.

The two additional amino acids enhance its binding affinity to the SNARE complex, theoretically allowing for more effective competition with the native SNAP-25 protein. This extended structure also confers greater stability against degradation in cosmetic formulations compared to Argireline.

Stay turned for the new raws list

Xraw-Peps_admin@protonmail.com

FDA Disclaimer

FDA Disclaimer: The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

Xraw-Peps, is a chemical supplier. We are not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Xraw-Peps is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption.


© Copyright 2024 - Xraw-Peps